Clinical Trials Logo

Recurrent Neuroblastoma clinical trials

View clinical trials related to Recurrent Neuroblastoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04500548 Withdrawn - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Start date: January 28, 2021
Phase: Phase 1
Study type: Interventional

This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment (refractory) and have an increased number of genetic changes. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tumor mutational burden (TMB) is the total amount of genetic changes or "mutations" found in tumor cells. Some studies in adults with cancer have shown that patients with a higher TMB (an increased number of genetic changes) are more likely to respond to immunotherapy drugs. There is also evidence that nivolumab and ipilimumab can shrink or stabilize cancer in adult patients with cancer. This study is being done to help doctors learn if the combination of nivolumab and ipilimumab can help children, adolescents, and young adults patients live longer.

NCT ID: NCT03209869 Withdrawn - Neuroblastoma Clinical Trials

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

Start date: March 12, 2018
Phase: Phase 1
Study type: Interventional

Subjects with relapsed or refractory neuroblastoma and osteosarcoma will receive ex-vivo expanded and activated natural killer (NK) cells from a haploidentical donor in conjunction with the immunocytokine, hu14.18-IL2.

NCT ID: NCT02011126 Withdrawn - Rhabdomyosarcoma Clinical Trials

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Start date: June 30, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well imetelstat sodium works in treating younger patients with relapsed or refractory solid tumors. Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01558778 Withdrawn - Clinical trials for Chronic Myelomonocytic Leukemia

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Start date: May 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant. Mechanical stimulation may limit, prevent, or reverse bone loss, increase muscle and cardiac performance, and improve overall health